Psychedelic Drugs Market Analysis

Drugs (Psilocybin, MethylenedioxyMethamphetamine, Lysergic Acid Diethylamide, Dimethyltryptamine)

The psilocybin segment in the psychedelic drugs market is estimated to hold 40%  of the revenue share by the end of 2037. The segment growth can be accredited to the increasing research and development. Researchers are increasingly looking to psilocybin and psychedelic drugs for the treatment of various psychiatric and neurological disorders such as pain, addiction, depression, terminal anxiety, and post-traumatic stress disorder (POST).

For instance, a multinational research team that studied the biosynthesis of psilocybin discovered new information on the composition and mechanism of action of the enzyme PsiM, which catalyzes the final two steps in the synthesis of psilocybin, which are two consecutive methylation processes.

Psilocybin, also known as magic mushroom, is naturally available and is often used as part of psilocybin-assisted therapy used essentially for conditions that are difficult to treat, such as addiction and fear of the end of life.

Application (Treatment Resistant Depression, Narcolepsy, Major Depressive Disorder, Opiate Addiction)

The major depressive disorder segment in the psychedelic drugs market is set to garner a notable share shortly. It is estimated that the increasing prevalence of depressive disorders will drive the growth of this segment. Depression is a common mental illness worldwide, with approximately 5% of adults suffering from it. The field is expected to grow as ongoing research and studies show MDMA to be a promising potential treatment for depression and other mood disorders. 

Our in-depth analysis of the global psychedelic drugs market includes the following segments